MANTECH Publications

Journal of Pharmaceutical Chemistry and Drug Formulation
Volume 8, Issue 1, January-April 2026
ISSN: 3108-0782 (Online)

Advanced Drug Delivery Systems (DDS): Innovations and Therapeutic Prospects

Birender Prasad[1], Jayant Thakur[2]

Associate Professor[1], Student[2]

Department of Pharmaceutical Chemistry

Sri Raghvendra College of Pharmacy

Corresponding Author Email: *Birenderprasad5@gmail.com[1]*

DOI: *https://doi.org/10.5281/zenodo.19694426*

ABSTRACT

The field of drug delivery has witnessed remarkable progress in recent decades, transitioning from conventional dosage forms to sophisticated systems capable of targeted, controlled, and stimuli-responsive drug release. Advanced drug delivery systems (DDS) aim to optimize therapeutic efficacy while minimizing side effects, improving patient compliance, and addressing challenges such as poor solubility, rapid clearance, and multidrug resistance. This review highlights the current landscape of advanced DDS, focusing on nanocarriers, polymeric systems, liposomes, micelles, dendrimers, hydrogels, and emerging technologies such as stimuli-responsive and biologically inspired delivery systems. Additionally, we discuss the clinical applications, challenges, and future directions of DDS, emphasizing the role of personalized medicine in shaping next-generation therapies.

KEYWORDS: *Drug delivery systems, nanocarriers, liposomes, stimuli-responsive delivery, polymeric nanoparticles, targeted therapy.*

INTRODUCTION

Drug delivery is a cornerstone of therapeutic intervention. Traditional oral and parenteral dosage forms often suffer from limitations such as poor bioavailability, nonspecific distribution, frequent dosing, and systemic side effects. Advanced DDS overcome these limitations by enhancing drug solubility, stability, and targeted delivery to specific tissues or

cells. The evolution of DDS has been driven by nanotechnology, polymer chemistry, and biotechnology, resulting in systems that are more efficient, responsive, and patient-friendly.

The goals of modern DDS include:

1. **Targeted delivery** – directing drugs specifically to diseased sites.
2. **Controlled release** – maintaining optimal drug concentrations over prolonged periods.
3. **Improved bioavailability** – enhancing solubility and absorption of poorly soluble drugs.
4. **Reduced toxicity** – minimizing adverse effects by avoiding systemic exposure.

CLASSIFICATION OF ADVANCED DRUG DELIVERY SYSTEMS

Advanced drug delivery systems (DDS) have evolved to overcome the limitations of conventional drug formulations, such as poor solubility, rapid metabolism, and non-specific distribution. These systems are designed to improve therapeutic efficacy, reduce side effects, and allow for controlled or targeted drug release. DDS can be broadly classified based on the **materials used**, the **physical structure**, or the **mechanism of drug release**. Key classifications include **lipid-based systems, polymeric nanoparticles, hydrogels and smart polymers, inorganic nanocarriers, and biologically inspired delivery systems**.

1. Lipid-Based Systems

Lipid-based drug delivery systems are among the most widely studied and clinically applied DDS. They exploit the biocompatibility and amphiphilic nature of lipids to encapsulate both hydrophilic and hydrophobic drugs. Lipid-based carriers can improve drug solubility, protect drugs from degradation, enhance cellular uptake, and allow for targeted delivery.

a) Liposomes

Structure and Composition:

Liposomes are spherical vesicles consisting of one or more phospholipid bilayers surrounding an aqueous core. The amphiphilic nature of phospholipids allows liposomes to encapsulate hydrophilic drugs within the aqueous core and hydrophobic drugs within the lipid bilayer. Liposome size typically ranges from 50 nm to several micrometers, depending on preparation methods.

Mechanism of Drug Delivery:

Upon administration, liposomes can fuse with cellular membranes or be internalized via endocytosis, releasing their cargo inside target cells. Liposomes can also be surface-modified with polyethylene glycol (PEGylation) to improve circulation time or with ligands (antibodies, peptides) for receptor-mediated active targeting.

Advantages:

- Biocompatible and biodegradable.
- Capable of encapsulating a wide variety of drugs.
- Reduce drug toxicity (e.g., cardiotoxicity of doxorubicin).
- Allow for surface modification to improve targeting.

Limitations:

- Physical and chemical instability (oxidation or hydrolysis of lipids).
- Rapid clearance by the reticuloendothelial system (RES).
- Costly and complex manufacturing processes.

Clinical Example:

- **Doxil® (PEGylated liposomal doxorubicin):** Approved for cancer therapy; reduces cardiotoxicity and allows for prolonged circulation.

b) Solid Lipid Nanoparticles (SLNs)

Structure and Composition:

SLNs are submicron-sized particles (50–1000 nm) composed of solid lipids that remain solid at both room and body temperatures. Lipids commonly used include glyceryl behenate, stearic acid, or triglycerides. Drugs are dispersed or dissolved in the solid lipid matrix.

Mechanism of Drug Delivery:

Drugs are released from SLNs either by diffusion through the lipid matrix or by erosion/degradation of the lipid carrier. The solid lipid core provides stability and protects the drug from chemical degradation.

Advantages:

- Controlled and sustained drug release.
- Good biocompatibility.
- High physical stability compared to liposomes.

Limitations:

- Limited drug loading capacity for hydrophilic drugs.
- Potential for lipid crystallization leading to drug expulsion.

Clinical Example:

- SLNs have been studied for oral delivery of poorly soluble drugs like curcumin and anticancer agents such as paclitaxel.

c) Nanostructured Lipid Carriers (NLCs)

Structure and Composition:

NLCs are an advanced generation of lipid nanoparticles designed to overcome SLN limitations. They consist of a blend of solid and liquid lipids, creating an imperfect crystalline matrix that allows higher drug loading and reduces drug expulsion.

Mechanism of Drug Delivery:

The mixed lipid matrix enables a more flexible drug release profile. NLCs can release drugs via diffusion, erosion, or stimuli-responsive mechanisms when combined with functional lipids or surface ligands.

Advantages:

- Enhanced drug loading compared to SLNs.
- Reduced drug leakage during storage.
- Ability to incorporate both hydrophilic and lipophilic drugs.

Limitations:

- Slightly more complex manufacturing than SLNs.
- Stability may be influenced by lipid composition and storage conditions.

Clinical Relevance:

- NLCs are being explored for transdermal drug delivery, topical formulations, and oral administration of poorly soluble drugs. They offer significant advantages in cosmetic and pharmaceutical industries due to their stability and biocompatibility.

Table 1: Comparison of Lipid-Based DDS

System	Composition	Advantages	Limitations
Liposomes	Phospholipid bilayer	Biocompatible, versatile	Rapid clearance, storage instability
SLNs	Solid lipids	Controlled release, scalable	Limited drug loading
NLCs	Mixture of solid & liquid lipids	High drug loading, reduced leakage	Complex preparation

2. Polymeric Nanoparticles (PNPs)

Polymeric nanoparticles (PNPs) are submicron-sized particles (typically 10–1000 nm) composed of natural or synthetic polymers that encapsulate, adsorb, or conjugate therapeutic agents. These systems have emerged as versatile carriers due to their **controlled drug release, biodegradability, and potential for targeted delivery**. PNPs can be engineered to release drugs over a prolonged period, protect drugs from degradation, and improve bioavailability.

a) Types of Polymers

- **Natural Polymers:**
  - Chitosan, alginate, gelatin, hyaluronic acid.
  - Biocompatible, biodegradable, and often mucoadhesive, making them suitable for oral, nasal, or ocular delivery.
  - Example: Chitosan nanoparticles have been used for insulin delivery due to their mucoadhesive and permeation-enhancing properties.

- **Synthetic Polymers:**
  - Poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polyethylene glycol (PEG).

- Offer tunable degradation rates, controlled release profiles, and surface modification possibilities.
- Example: PLGA nanoparticles are widely used for chemotherapeutic drugs such as paclitaxel and docetaxel due to their sustained release and biocompatibility.

b) Dendrimers

Structure and Characteristics:

Dendrimers are highly branched, tree-like macromolecules with a central core, repetitive branching units, and multiple surface functional groups. This structure allows precise control over size, shape, and surface chemistry, enabling **multivalent interactions with drugs or targeting ligands**.

Drug Encapsulation/Conjugation:

- Drugs can be physically encapsulated in the internal cavities or chemically conjugated to the terminal functional groups.
- Surface modification with polyethylene glycol (PEGylation) or targeting ligands improves solubility, reduces immunogenicity, and enhances tissue specificity.

Advantages:

- Precise molecular architecture allows reproducible drug loading.
- Multivalent surface allows targeting, imaging, or combination therapy.
- High water solubility and stability.

Limitations:

- Synthesis is complex and expensive.
- Potential cytotoxicity if cationic dendrimers are used at high concentrations.

Clinical Example:

- PAMAM dendrimers have been explored for delivering anticancer drugs like doxorubicin and methotrexate.



Figure 1: Schematic Representation of Polymeric Nanocarriers

3. Hydrogels and Smart Polymers

Hydrogels are **three-dimensional, hydrophilic polymer networks** capable of absorbing large amounts of water or biological fluids. Their porous structure allows drug molecules to be physically entrapped or chemically conjugated. Drug release typically occurs via **diffusion through the hydrogel matrix** or **swelling-induced release**. Hydrogels are highly biocompatible and have been widely applied in tissue engineering, wound healing, and drug delivery.

a) Smart Hydrogels

Smart hydrogels, also called **stimuli-responsive hydrogels**, can **alter their physical or chemical properties** in response to environmental stimuli. This property allows for **on-demand, site-specific drug release**, minimizing systemic side effects.

Types of Smart Hydrogels:

1. **pH-Sensitive Hydrogels**

- Designed to respond to pH changes in the local environment.
- Tumor tissues and inflamed areas often exhibit acidic microenvironments (pH 6–6.8), whereas normal tissues are near neutral (pH 7.4).
- Drugs are released as the hydrogel swells or degrades in acidic conditions.
- **Example:** Poly(acrylic acid)-based hydrogels for anticancer drug delivery.

2. **Thermosensitive Hydrogels**

- Respond to temperature changes.
- Typically, **sol-gel transition occurs near physiological temperature (37°C)**.
- These hydrogels are injected as liquids and solidify at the target site, providing sustained release.
- **Example:** Pluronic F127 hydrogel for localized delivery of chemotherapeutics or growth factors.

3. **Enzyme-Responsive Hydrogels**

- Designed to degrade in the presence of specific enzymes overexpressed in diseased tissues (e.g., matrix metalloproteinases in tumors).
- Enable **site-specific drug release** with minimal systemic exposure.
- **Example:** Peptide-crosslinked hydrogels releasing drugs in response to tumor-associated proteases.

Advantages:

- High water content ensures biocompatibility.
- Can encapsulate a wide range of drugs (small molecules, proteins, nucleic acids).
- Allows **controlled, sustained, and stimuli-responsive release**.

Limitations:

- Mechanical strength can be low.
- Swelling and drug release kinetics may be difficult to control precisely.
- Some hydrogels may exhibit burst release under certain conditions.

Clinical Relevance:

- Hydrogels are used in wound dressings (e.g., antibiotic-loaded), localized cancer therapy, ocular drug delivery, and tissue engineering scaffolds.
- Thermosensitive hydrogels are being tested in clinical trials for **localized chemotherapy** and **post-surgical drug administration**.

4. **Inorganic Nanocarriers**

Inorganic nanoparticles offer **high physical and chemical stability**, ease of surface

functionalization, and **multimodal applications**, including **drug delivery, imaging, and photothermal therapy**.

a) Gold Nanoparticles (AuNPs)

- Gold nanoparticles have unique optical and electronic properties, making them ideal for **photothermal therapy** and imaging-guided drug delivery.
- Drugs can be conjugated via thiol or amine groups on the surface.
- **Advantages:**
  - Biocompatible and inert.
  - Allows combination therapy (drug delivery + photothermal therapy).
  - Can be targeted with ligands or antibodies.
- **Limitations:**
  - Potential long-term accumulation in organs.
  - Surface functionalization is required to prevent aggregation.

b) Mesoporous Silica Nanoparticles (MSNs)

- MSNs have **high surface area and tunable pore size**, which enables **high drug loading and controlled release**.
- Surface can be modified with polymers, ligands, or stimuli-responsive moieties.
- **Advantages:**
  - High drug loading efficiency.
  - Stable under physiological conditions.
  - Can be engineered for stimuli-responsive release (pH, redox, enzymes).
- **Limitations:**
  - Biodegradability in vivo is slower compared to organic carriers.
  - Potential cytotoxicity if surface is not properly modified.

Clinical Relevance:

- AuNPs and MSNs are increasingly explored for **cancer therapy, gene delivery, and imaging-guided therapy**.
- Theranostic applications (simultaneous therapy + diagnostics) are a major research focus.

4. Biologically Inspired Delivery Systems

Biologically inspired DDS leverage natural mechanisms of transport and cellular communication, offering **high biocompatibility, low immunogenicity, and targeted delivery**.

a) Exosomes

- **Cell-derived extracellular vesicles** (30–150 nm) that naturally transport proteins, nucleic acids, and small molecules between cells.
- Drugs can be loaded into exosomes via incubation, electroporation, or genetic engineering.
- **Advantages:**
  - Low immunogenicity.
  - Natural targeting abilities based on origin.
  - Capable of crossing biological barriers like the blood-brain barrier.
- **Limitations:**
  - Complex isolation and purification.
  - Limited large-scale production.

b) Bacteria-Mediated Delivery

- Engineered bacteria can selectively colonize hypoxic tumor environments or inflamed tissues and release therapeutic agents.
- **Advantages:**
  - Can penetrate poorly vascularized tissues.
  - Capable of sustained local drug release.
- **Limitations:**
  - Potential immune response.
  - Safety concerns requiring careful strain selection.

c) Peptide-Based Carriers

- Short peptides can be designed to target specific cell surface receptors or intracellular pathways.
- Peptides can **direct DDS to tumor cells, inflamed tissue, or infected sites**, enhancing specificity.

- **Advantages:**
  - High selectivity and biocompatibility.
  - Can be combined with other DDS like nanoparticles or hydrogels.
- **Limitations:**
  - Susceptible to enzymatic degradation in vivo.
  - Peptide synthesis and functionalization can be costly.

Clinical Relevance:

- Exosomes are being tested for **gene therapy, siRNA delivery, and cancer immunotherapy**.
- Bacteria-mediated DDS are in **early clinical trials for solid tumors**.
- Peptide-based DDS are applied in **targeted anticancer therapies** and **vaccine delivery**.

TARGETED DRUG DELIVERY STRATEGIES

Targeted drug delivery strategies are designed to **increase drug accumulation at diseased sites while minimizing exposure to healthy tissues**, thereby improving therapeutic efficacy and reducing side effects. Achieving precise targeting is particularly critical in treatments such as **cancer therapy, infectious disease management, and gene therapy**. Drug delivery systems (DDS) employ both **passive and active targeting mechanisms** and often integrate **stimuli-responsive features** for on-demand release.

1. Passive Targeting

Mechanism:

Passive targeting leverages the **enhanced permeability and retention (EPR) effect**, a phenomenon observed in tumors and inflamed tissues. Tumor vasculature is typically **abnormal, leaky, and poorly organized**, allowing nanoparticles (typically 10–200 nm) to preferentially accumulate in the tumor interstitium. Furthermore, tumors often lack efficient lymphatic drainage, which helps retain nanoparticles at the site.

Advantages:

- No need for specific ligands or surface modifications.
- Exploits natural physiological differences between diseased and normal tissues.
- Simple formulation strategy for nanoparticles, liposomes, and micelles.

Limitations:

- EPR effect varies between patients and tumor types.
- Limited accumulation in hypovascularized tumors.
- Non-specific accumulation in organs like the liver and spleen may still occur.

Clinical Examples:

- **Doxil®**: PEGylated liposomal doxorubicin utilizes EPR for passive tumor targeting.
- Nanoparticles for paclitaxel delivery also rely on passive accumulation in solid tumors.

Key Point:

While passive targeting is widely used, variability in the EPR effect necessitates complementary strategies such as **active targeting or stimuli-responsive release**.

2. Active Targeting

Mechanism:

Active targeting involves **surface modification of DDS with ligands** that bind specifically to receptors or molecules overexpressed on target cells. These ligands can be:

- **Antibodies** (monoclonal or fragment-based)
- **Peptides** (e.g., RGD peptide targeting integrins)
- **Aptamers** (short nucleic acid sequences binding specific proteins)
- **Small molecules** (e.g., folic acid targeting folate receptors)

When DDS bind to target cell receptors, they are typically internalized via **receptor-mediated endocytosis**, allowing intracellular drug delivery.

Advantages:

- Higher specificity reduces off-target toxicity.
- Enhances cellular uptake and efficacy.
- Can deliver multiple drugs or imaging agents simultaneously.

Limitations:

- Complex and costly ligand conjugation.
- Potential immunogenicity of ligands (e.g., antibodies).

- Receptor expression may vary among patients or tumor cells, leading to heterogeneous targeting.

Clinical Examples:

- **Folate-conjugated nanoparticles** for targeting folate receptor-positive tumors.
- **HER2-targeted liposomal doxorubicin** for HER2-positive breast cancer.
- **Peptide-functionalized micelles** for integrin-overexpressing tumors.

Key Point:

Active targeting is often combined with passive targeting to **maximize tumor accumulation and cellular internalization**, forming a dual-targeting approach.

3. Stimuli-Responsive Systems

Mechanism:

Stimuli-responsive DDS are engineered to release their cargo in response to **internal physiological stimuli** or **external physical triggers**. These systems enable **on-demand and site-specific drug release**, minimizing systemic exposure.

Types of Stimuli:

1. **Internal Stimuli:**

- **pH-sensitive systems:** Exploit acidic tumor microenvironments or intracellular endosomes/lysosomes.
- **Redox-sensitive systems:** Utilize higher glutathione concentrations inside cancer cells for drug release.
- **Enzyme-responsive systems:** Degrade in the presence of disease-associated enzymes (e.g., MMPs in tumors).

2. **External Stimuli:**

- **Light-sensitive systems:** Release drugs upon exposure to specific wavelengths.
- **Magnetic field-responsive systems:** Magnetically guided nanoparticles deliver drugs to target tissues.
- **Ultrasound-sensitive systems:** Ultrasound triggers drug release or enhances tissue **penetration**.

Advantages:

- Spatial and temporal control over drug release.
- Reduced systemic toxicity.
- Can be combined with imaging modalities for theranostic applications.

Limitations:

- Complexity of design and synthesis.
- External stimuli require specialized equipment and may have limited tissue penetration (e.g., light in deep tumors).
- In vivo variability of stimuli (e.g., pH gradients) may affect reproducibility.

Clinical Examples:

- **pH-sensitive liposomes** delivering doxorubicin in acidic tumor environments.
- **Magnetically guided iron oxide nanoparticles** for hyperthermia combined with drug delivery.
- **Light-triggered polymeric nanoparticles** for localized anticancer therapy.



Figure 2: Stimuli-Responsive DDS Mechanisms

CLINICAL APPLICATIONS OF ADVANCED DDS

Advanced DDS have found applications in various therapeutic areas:

- **Oncology:** Liposomal doxorubicin, PEGylated nanoparticles for targeted cancer therapy.

- **Neurology:** Nanocarriers crossing the blood-brain barrier for neurodegenerative disease treatment.
- **Infectious Diseases:** Nanoparticles for sustained antibiotic release, reducing dosing frequency.
- **Cardiovascular Diseases:** Polymeric stents and drug-eluting systems for controlled vascular therapy.

Table 2: Selected FDA-Approved Advanced DDS

Drug/Formulation	DDS Type	Indication	Key Benefits
Doxil®	Liposome	Cancer	Reduced cardiotoxicity
Abraxane®	Albumin NP	Breast Cancer	Enhanced solubility & targeting
Onpattro®	Lipid NP	hATTR amyloidosis	RNAi delivery to liver

CHALLENGES IN DDS DEVELOPMENT

Despite significant advancements, several challenges remain:

1. **Manufacturing and Scalability:** Complex synthesis methods can hinder large-scale production.
2. **Stability:** Nanocarriers may undergo aggregation or premature drug leakage.
3. **Regulatory Hurdles:** Limited standardized guidelines for novel DDS.
4. **Biocompatibility and Toxicity:** Long-term safety remains a concern, especially for inorganic and synthetic systems.
5. **Targeting Efficiency:** Achieving precise delivery while avoiding immune clearance is still challenging.

FUTURE PERSPECTIVES

The future of DDS lies in **personalized medicine**, combining patient-specific biomarkers with intelligent delivery platforms. Emerging technologies include:

- **Artificial Intelligence (AI) for DDS Design:** Predicting drug-carrier interactions, optimizing release kinetics.
- **Multifunctional DDS:** Simultaneous imaging, targeting, and therapy.
- **Gene and RNA Delivery:** CRISPR/Cas9 and RNAi therapeutics delivered via nanoparticles.

- **Biodegradable and Self-Assembling Systems:** Reducing long-term accumulation and enhancing biocompatibility.

Integration of these innovations promises highly efficient, safe, and customizable therapeutic strategies.

CONCLUSION

Advanced drug delivery systems have transformed modern pharmacotherapy, offering targeted, controlled, and patient-friendly therapeutic options. Lipid-based carriers, polymeric nanoparticles, hydrogels, and biologically inspired systems have broadened the scope of treatment modalities, particularly in oncology, neurology, and infectious diseases. Despite challenges in manufacturing, stability, and regulatory approval, ongoing research in stimuli-responsive, multifunctional, and personalized DDS holds tremendous potential for the next generation of therapeutics. Collaborative efforts among pharmaceutical scientists, clinicians, and regulatory authorities are essential to translate these innovations into safe and effective clinical applications.

REFERENCES

1. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. *Science*. 2004;303(5665):1818–1822.
2. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. *Clin Pharmacol Ther*. 2008;83(5):761–769.
3. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. *Annu Rev Med*. 2012;63:185–198.
4. Torchilin VP. Multifunctional nanocarriers. *Adv Drug Deliv Rev*. 2012;64:302–315.
5. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. *Adv Drug Deliv Rev*. 2014;66:2–25.
6. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. *Nat Rev Drug Discov*. 2010;9(8):615–627.
7. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms and applications. *Chem Rev*.

2016;116(4):2602–2663.

8. Mitragotri S, Anderson DG, Chen X, et al. Accelerating the translation of nanomaterials in biomedicine. *ACS Nano*. 2015;9(7):6644–6654.
9. Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. *Nat Rev Mater*. 2016;1:16071.
10. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls, and (pre-) clinical progress. *J Control Release*. 2012;161:175–187.

Cite as:

Birender Prasad, Jayant Thakur (2026). Advanced Drug Delivery Systems (DDS): Innovations and Therapeutic Prospects, Journal of Pharmaceutical Chemistry and Drug formulation, 8(1), 12-28.
https://doi.org/10.5281/zenodo.19694426